Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo®), administered as a single intramuscular dose between 32 and 36 weeks of gestation, induces maternal IgG that is transferred to the fetus and confers passive protection during the first six months of life. In the phase 3 MATISSE trial, vaccination demonstrated 81.8% efficacy against severe RSV lower respiratory tract infection within 90 days of birth and 69.4% within 180 days, alongside reductions in hospitalization. The safety profile was favorable, with predominantly mild and transient adverse events; a numerical imbalance in preterm birth remains under surveillance and underlies the precautionary gestational window. Maternal vaccination and long-acting monoclonal antibodies (nirsevimab) are best regarded as complementary rather than competing strategies. Current evidence supports maternal immunization as one of the most effective measures to reduce the burden of RSV disease in early infancy.
Infection by the varicella–zoster virus (VZV) during pregnancy is uncommon but clinically relevant, since it may compromise both the mother and the fetus. Although varicella is generally benign and self-limited in childhood, the physiological and immunological changes in pregnancy predispose individuals to more severe forms of the disease, with pneumonia representing the main maternal complication and a leading cause of morbidity and mortality. Vertical transmission may result in congenital varicella syndrome, the most severe fetal consequence, whose risk is greatest between the 13th and 20th weeks of gestation, or in severe neonatal varicella when maternal infection occurs in the peripartum period. This article presents a narrative review of the literature. To enhance methodological transparency and reproducibility, key principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were applied to the literature search and study selection process. Searches were conducted in the PubMed/MEDLINE and SciELO databases, and 32 studies were included in the narrative synthesis. The review addresses the virology, pathophysiology, and epidemiology of VZV infection, including differences between temperate and tropical regions, as well as its clinical manifestations and maternal, fetal, and neonatal complications. Diagnosis is predominantly clinical, with the polymerase chain reaction being the most sensitive and specific confirmatory method and serology being useful mainly for the assessment of maternal immunity. Management encompasses the assessment of susceptibility, post-exposure prophylaxis according to current guideline recommendations, and early antiviral treatment of established infection. Preconception and postpartum vaccination remain the main preventive strategies. Despite recent advances, important gaps persist regarding prophylactic strategies and the long-term safety of antivirals during pregnancy.
Human papillomavirus (HPV) vaccination has traditionally targeted girls and adolescents before sexual debut, when its preventive potential is greatest. However, many women reach adulthood unvaccinated or incompletely vaccinated, a gap widened by the COVID-19 pandemic. This narrative review summarizes the current evidence on HPV vaccination in adult women and its implications for gynecological practice. Sexual debut, previous infection, or a positive HPV test does not preclude benefit, because few women have been exposed to all vaccine types; nevertheless, the vaccine is prophylactic and does not treat established infection or lesions. In women aged 27 to 45 years, trials show favorable immunogenicity, efficacy, and safety, and vaccination is recommended through shared clinical decision-making that considers prior exposure and the risk of new exposures. Evidence above 45 years of age remains scarce. After excisional treatment of cervical intraepithelial neoplasia grade 2 or worse, meta-analyses predominantly based on observational studies suggest lower recurrence rates following adjuvant vaccination, although this benefit has not been consistently confirmed by randomized controlled trials. We also discuss additional vaccination with the nonavalent vaccine after bivalent or quadrivalent series, single-dose schedules, people living with HIV, and cervical screening in vaccinated women, in whom HPV-based testing maintains better performance than cytology. Missed opportunities remain common, and the absence of a recommendation from a health care professional is among the main reasons adults remain unvaccinated. Reviewing vaccination history at every gynecological visit, combined with individualized counseling, may help close the gap between vaccinated young cohorts and unvaccinated adult women and support cervical cancer elimination goals.